New combo targets pancreatic cancer before surgery
NCT ID NCT05209074
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times
Summary
This early-phase trial tests whether adding the targeted drug ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer will take part. The main goal is to find the safest dose and see how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.